Đặc trưng của các tác nhân tương phản dựa trên nanoparticle cho hình ảnh cộng hưởng từ phân tử

Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30:1259–1267 Alford R, Ogawa M, Choyke PL, Kobayashi H (2009) Molecular probes for the in vivo imaging of cancer. Mol BioSyst 5:1279–1291 Artemov D, Bhujwalla ZM, Bulte JW (2004) Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol 5:485–494 Benet LZ (2010) Clearance (nee Rowland) concepts: a downdate and an update. J Pharmacokinet Pharmacodyn 37:529–539 Blamire AM (2008) The technology of MRI—the next 10 years? Br J Radiol 81:601–617 Brown SC, Palazuelos M, Sharma P, Powers KW, Roberts SM, Grobmyer SR, Moudgil BM (2010) Nanoparticle characterization for cancer nanotechnology and other biological applications. Methods Mol Biol 624:39–65 Bulte JW (2009) In vivo MRI cell tracking: clinical studies. AJR Am J Roentgenol 193:314–325 Cheng KT, Menkens A, Bryant S, Sullivan DC (2007) NIH MICAD initiative and guest author program opportunities. J Nucl Med 48:19N Cheng Z, Thorek DL, Tsourkas A (2010) Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl 49:346–350 Chopra A, Shan L, Eckelman WC, Leung K, Mankens AE (2011) Important parameters to consider for the characterization of PET and SPECT imaging probes. Nucl Med Biol 38:1079–1084 Chopra A, Shan L, Eckelman WC, Leung K, Latterner M, Bryant S, Menkens A (2012) Molecular imaging and contrast agent database (MICAD): evolution and progress. Mol Imaging Biol 14:4–13 Cipolla L, Gregori M, So PW (2011) Glycans in magnetic resonance imaging: determinants of relaxivity to smart agents, and potential applications in biomedicine. Curr Med Chem 18:1002–1018 Corsi DM, Platas-Iglesias C, Van Bekkum H, Peters JA (2001) Determination of paramagnetic lanthanide(III) concentrations from bulk magnetic susceptibility shifts in NMR spectra. Magn Reson Chem 39:723–726 de la Fuente JM, Grazu V (2012) Nanotechnology: inorganic nanoparticles vs organic nanoparticles, vol 4. Elsevier, Amsterdam Debbage P, Jaschke W (2008) Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol 130:845–875 Delikatny EJ, Poptani H (2005) MR techniques for in vivo molecular and cellular imaging. Radiol Clin North Am 43:205–220 Di Marco M, Guilbert I, Port M, Robic C, Couvreur P, Dubernet C (2007a) Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm 331:197–203 Di Marco M, Sadun C, Port M, Guilbert I, Couvreur P, Dubernet C (2007b) Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine 2:609–622 Eckelman WC, Kilbourn MR, Joyal JL, Labiris R, Valliant JF (2007) Justifying the number of animals for each experiment. Nucl Med Biol 34:229–232 Eckelman WC, Kilbourn MR, Mathis CA (2009) Specific to nonspecific binding in radiopharmaceutical studies: it’s not so simple as it seems! Nucl Med Biol 36:235–237 Fadeel B, Garcia-Bennett AE (2010) Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 62:362–374 Fox GB, Chin CL, Luo F, Day M, Cox BF (2009) Translational neuroimaging of the CNS: novel pathways to drug development. Mol Interv 9:302–313 Gaumet M, Vargas A, Gurny R, Delie F (2008) Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69:1–9 Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE (2007) Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2:249–255 Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–4021 Haun JB, Yoon TJ, Lee H, Weissleder R (2010) Magnetic nanoparticle biosensors. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:291–304 Hellman RN (2011) Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 31:310–316 Hermann P, Kotek J, Kubicek V, Lukes I (2008) Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Trans 21:3027–3047 Karmali PP, Simberg D (2011) Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 8:343–357 Koh TS, Bisdas S, Koh DM, Thng CH (2011) Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI. J Magn Reson Imaging 34:1262–1276 Koole R, van Schooneveld MM, Hilhorst J, Castermans K, Cormode DP, Strijkers GJ, Donega CD, Vanmaekelbergh D, Griffioen AW, Nicolay K, Fayad ZA, Meijerink A, Mulder WJM (2008) Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem 19:2471–2479 Langley J, Liu W, Jordan EK, Frank JA, Zhao Q (2011) Quantification of SPIO nanoparticles in vivo using the finite perturber method. Magn Reson Med 65:1461–1469 Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN (2008) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 108:2064–2110 Leung K, Chopra A, Shan L, Eckelman WC, Menkens A (2012) Essential parameters to consider for the characterization of optical imaging probes. Nanomed 7:1101–1107 Lodhia J, Mandarano G, Ferris N, Eu P, Cowell S (2010) Development and use of iron oxide nanoparticles (Part 1): synthesis of iron oxide nanoparticles for MRI. Biomed Imaging Interv J 6:e12 Lowe MP (2004) Activated MR contrast agents. Curr Pharm Biotechnol 5:519–528 Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, Maecke HR (2005) Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 46:823–830 Makowski MR, Wiethoff AJ, Jansen CH, Botnar RM (2009) Molecular imaging with targeted contrast agents. Top Magn Reson Imaging 20:247–259 Mankoff DA, O’Sullivan F, Barlow WE, Krohn KA (2007) Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol 14:398–405 Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545–580 Morcos SK (2008) Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 66:175–179 Pakzad F, Ell PJ, Carrio I (2005) Molecular imaging in animal models of disease—every little detail counts! Eur J Nucl Med Mol Imaging 32:899–900 Ptak K, Farrell D, Panaro NJ, Grodzinski P, Barker AD (2010) The NCI alliance for nanotechnology in cancer: achievement and path forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:450–460 Rosenblum LT, Kosaka N, Mitsunaga M, Choyke PL, Kobayashi H (2010) In vivo molecular imaging using nanomaterials: general in vivo characteristics of nano-sized reagents and applications for cancer diagnosis. Mol Membr Biol 27:274–285 Sayes CM, Warheit DB (2009) Characterization of nanomaterials for toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:660–670 Schladt TD, Schneider K, Schild H, Tremel W (2011) Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment. Dalton Trans 40:6315–6343 Schrand AM, Rahman MF, Hussain SM, Schlager JJ, Smith DA, Syed AF (2010) Metal-based nanoparticles and their toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:544–568 Shah B, Anderson SW, Scalera J, Jara H, Soto JA (2011) Quantitative MR imaging: physical principles and sequence design in abdominal imaging. Radiographics 31:867–880 Shan L, Wang S, Sridhar R, Bhujwalla ZM, Wang PC (2007) Dual probe with fluorescent and magnetic properties for imaging solid tumor xenografts. Mol Imaging 6:85–95 Sherry AD, Caravan P, Lenkinski RE (2009) Primer on gadolinium chemistry. J Magn Reson Imaging 30:1240–1248 Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M (2009) Preparation and in vivo imaging of PEG-poly(l-lysine)-based polymeric micelle MRI contrast agents. J Control Release 136:14–20 Shiraishi K, Kawano K, Maitani Y, Yokoyama M (2010) Polyion complex micelle MRI contrast agents from poly(ethylene glycol)-b-poly(l-lysine) block copolymers having Gd-DOTA; preparations and their control of T(1)-relaxivities and blood circulation characteristics. J Control Release 148:160–167 Tao L, Hu W, Liu Y, Huang G, Sumer BD, Gao J (2011) Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp Biol Med (Maywood) 236:20–29 Tei L, Mazooz G, Shellef Y, Avni R, Vandoorne K, Barge A, Kalchenko V, Dewhirst MW, Chaabane L, Miragoli L, Longo D, Neeman M, Aime S (2010) Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity. Contrast Media Mol Imaging 5:213–222 Tinkle SS (2010) Maximizing safe design of engineered nanomaterials: the NIH and NIEHS research perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:88–98 Weissleder R (2006) Molecular imaging in cancer. Science 312:1168–1171 Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 152:167–173